PT - JOURNAL ARTICLE AU - Rachael Piltch-Loeb AU - Nigel Harriman AU - Julia Healey AU - Marco Bonetti AU - Veronica Toffolutti AU - Marcia A Testa AU - Max Su AU - Elena Savoia TI - COVID-19 Vaccine Concerns about Safety, Effectiveness and Policies in the United States, Canada, Sweden, and Italy among Unvaccinated Individuals AID - 10.1101/2021.09.09.21263328 DP - 2021 Jan 01 TA - medRxiv PG - 2021.09.09.21263328 4099 - http://medrxiv.org/content/early/2021/09/10/2021.09.09.21263328.short 4100 - http://medrxiv.org/content/early/2021/09/10/2021.09.09.21263328.full AB - Despite the effectiveness of the COVID-19 vaccine, global vaccination distribution efforts have thus far had varying levels of success. Vaccine hesitancy remains a threat to vaccine uptake. This study has four objectives: 1) describe and compare vaccine hesitancy proportions by country; 2) categorize vaccine-related concerns; 3) rank vaccine-related concerns; and 4) compare vaccine-related concerns by country and hesitancy status in four countries- the United States, Canada, Sweden, and Italy. Using the Pollfish survey platform, we sampled 1000 respondents in Canada, Sweden, and Italy and 750 respondents in the United States between May 21-28, 2021. Results showed vaccine related concerns varied across three topical areas- vaccine safety and government control, vaccine effectiveness and population control, and freedom. For each thematic area, the top concern was statistically significantly different in each country and among the hesitant and non-hesitant subsamples within each county. Understanding the specific concerns among individuals when it comes to the COVID-19 vaccine can help to inform public communications and identify which, if any, salient narratives, are global.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project received funding from the NATO Science for Peace and Security Programme (grant number SPS.MYPG5556), the US Department of Homeland Security (DHS), Science and Technology Directorate (Cooperative Agreement Number: 2015-ST-108-FRG005) and Swedish Contingency Agency (MSB). The content of this manuscript as well as the views and discussions expressed are solely those of the authors and do not necessarily represent the official views of any of the above institutions, nor does the mention of trade names, commercial practices, or organizations imply endorsement by the US government.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol and survey instrument were approved by the Harvard T.H. Chan School of Public Health Institutional Review Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available upon request from the authors.